Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours
Shanghai Henlius Biotech, Inc. (2696.HK) today announced that it has entered into a global collaboration and license agreement with Amberstone Biosciences (“Amberstone”), a U.S.-based biotechnology company dedicated to developing next-generation tumour-activated antibody therapeutics. The collaboration will leverage Amberstone’s proprietary T-MATE™ (Tumour Microenvironment Activated ThErapeutics) platform to develop conditionally activated T-cell engagers (TCEs) based on up to two targets designated by Henlius for the treatment of solid tumours.
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib